Rheumatology

TNF Inhibitors

Questions discussed in this category

Do you use conventional DMARDs aside from methotrexate to prevent anti-drug antibody development for patients on infliximab?

3 Answers available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

Do you switch to certolizumab in RA patients who are doing well on other TNFis and planning to become pregnant?

1 Answer available

How does a history of splenectomy alter how you counsel patients on the infection risk of TNF inhibitors or other biologics?

1 Answer available

Would you use an anti-IL 17 over an anti-TNFa as your first line biologic in psoriatic arthritis?

Have the SPIRIT H2H and EXCEED data changed your practice?

1 Answer available

What is your work up and management for patients who develop neuropathy on a TNF inhibitor?

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

Are subcutaneous RA therapies less effective in obese patients?

1 Answer available

Do you use precision medicine tools (such as RNA testing, PRISM-RA) in clinical practice before starting a TNF inhibitor for RA?

https://www.prismra.com

2 Answers available

Would you re-challenge patients who have had a TNF-associated paradoxical adverse event (such as inflammatory bowel disease) with a different TNF inhibitor?

1 Answer available

What do you try in patients with IBD-related spondyloarthritis with predominantly axial symptoms who are refractory to TNF inhibitors?

1 Answer available

Papers discussed in this category

Annals of the rheumatic diseases, 2017-08

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

Lancet (London, England), 2018-12-01

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Lancet, 2019 Nov 12

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

Cochrane Database Syst Rev, 2014 Oct 23

Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.

Arthritis Rheumatol, 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Ann. Rheum. Dis., 2019 Sep 28

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Lancet,

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Journal of psoriasis and psoriatic arthritis, 2019-04

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Clin. Rheumatol., 2017 Aug 18

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

N Engl J Med,

Clinical practice. Care of the asplenic patient.

Mediterr J Rheumatol, 2020 Jun 11

Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies.

Rheumatology

TNF Inhibitors

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology